IAS 2022: Metabolic complications of newer HIV drugs in older people
1 December 2022. Related: Conference reports, Weight, diabetes, metabolic complications.
Conference reports
14th International Workshop on HIV & Pediatrics
3 October 2022. Related: Conference reports.
First paediatric pharmacokinetic data of dolutegravir in combination with a TAF-based NRTI backbone
3 October 2022. Related: Conference reports, Paediatric care.
24th International AIDS Conference (AIDS 2022): further reports
3 October 2022. Related: Conference reports.
AIDS 2022: Efficacy of DTG- vs EFV-based first-line ART in advanced HIV with CD4 <50 cells/mm3
3 October 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
AIDS 2022: Gender-affirming hormones, weight gain and ART
3 October 2022. Related: Conference reports, PK and drug interactions, Side effects.
24th International AIDS Conference (AIDS 2022)
1 September 2022. Related: Conference reports.
Dolutegravir no longer linked to higher risk of neural tube defects: latest update from the Tsepamo study
1 September 2022. Related: Conference reports, Pregnancy.
Weight gain with dolutegravir and TAF in ADVANCE study continues out to week 192
1 September 2022. Related: Conference reports, Women's health.
VRC01 added to early ART in infants did not reduce viral reservoir
1 September 2022. Related: Conference reports, Paediatric care.
Using PrEP during pregnancy is safe for children
1 September 2022. Related: Conference reports, Pregnancy, Paediatric care.
Long-acting CAB/RPV injections have a similar weight and lipid profile to dolutegravir-based oral ART
1 September 2022. Related: Conference reports.
Montreal’s response to monkeypox: rapid vaccine rollout, 39 breakthrough infections
1 September 2022. Related: Conference reports, mpox.
Summary of 620 cases of monkeypox seen at three London clinics
1 September 2022. Related: Conference reports, mpox.
Advances in HIV cure-related research: IAS workshop now online
1 September 2022. Related: Conference reports.
24th International AIDS Conference (AIDS 2022): first reports
3 August 2022. Related: Conference reports.
Dolutegravir-based ART in children and adolescents: effective in six African countries
3 August 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Early data on injecting CAB/RPV-LA into thigh muscle
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Simplifed lenacapavir dosing: PK results in HIV negative study
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Doxycycline PEP significantly reduces STIs in people at high risk of infections
3 August 2022. Related: Conference reports, Coinfections and complications.
Another possible HIV cure case after stem cell transplantation for cancer; example of extended post-treatment control in Spain
3 August 2022. Related: Conference reports, Cure-related research.
Other cure-related sessions at AIDS 2022
3 August 2022. Related: Conference reports, Cure-related research.
Selected reports launched at AIDS 2022
3 August 2022. Related: Conference reports, On the web.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): final report
1 July 2022. Related: Conference reports.
CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results
1 July 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): further reports
1 June 2022. Related: Conference reports.
CROI 2022: Updates from the VESTED study
1 June 2022. Related: Conference reports, Treatment strategies.
CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART
1 June 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
2 May 2022. Related: Conference reports.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
CROI 2022: Other COVID-19 studies
2 May 2022. Related: Conference reports, Coinfections and complications, COVID-19.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports
1 April 2022. Related: Conference reports.
CROI 2022: Webcasts now online and open access
1 April 2022. Related: Conference reports.
CROI 2022: Islatravir studies for HIV treatment and PrEP
1 April 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses
1 April 2022. Related: Conference reports, Coinfections and complications, COVID-19: long COVID, COVID-19.
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART in the REPRIEVE study
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: UK study shows PEP is started earlier using home starter packs
1 April 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Summary of 14 key studies on HIV and liver disease
1 April 2022. Related: Conference reports, Hepatitis coinfection.
CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs
1 April 2022. Related: Conference reports, Cure-related research.
29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports
1 March 2022. Related: Conference reports.
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Fourth potential stem cell HIV cure – in a US woman using donor cord cells
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Targetting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
1 March 2022. Related: Conference reports, Paediatric care, Cure-related research.
CROI 2022: AAV8-VRC07 vaccine generates new bNAb production in HIV positive people for up to three years
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: No impact from high-dose vitamin D3 on reducing the HIV viral reservoir
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana
1 March 2022. Related: Conference reports, Women's health, Pregnancy.
CROI 2022: ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Other studies on anal cancer
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Telomere shortening associated with TAF but not TDF in CHARTER study
1 March 2022. Related: Conference reports, Basic science and immunology, Ageing and life expectancy.
CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: LEAP Workshop online: research into long-acting drugs
1 March 2022. Related: Conference reports, On the web.
CROI 2022 to only be virtual: programme online
7 February 2022. Related: Conference reports.
18th International European AIDS Conference (EACS 2021)
20 December 2021. Related: Conference reports.
EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?
20 December 2021. Related: Conference reports, HIV prevention and transmission.
European AIDS Clinical Society honours Simon Collins for longstanding contribution to the field of HIV
20 December 2021. Related: Conference reports, Treatment advocacy.
18th International European AIDS Conference (EACS 2021)
30 November 2021. Related: Conference reports.
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.